SOT 203
Alternative Names: SOT-203Latest Information Update: 01 Mar 2022
At a glance
- Originator SOTIO
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Interleukin-15 receptor agonists; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Feb 2022 Preclinical trials in Cancer in Czech Republic (Parenteral) (SOTIO pipeline, February 2022)
- 11 Feb 2022 Preclinical trials in Cancer in USA (Parenteral) (SOTIO pipeline, February 2022)